Search

Your search keyword '"Hancock, SJ"' showing total 2 results
Start Over Author "Hancock, SJ" Publisher wiley
2 results on '"Hancock, SJ"'

1. Developing clinical indicators for oncology: the inaugural cancer care indicator set for the Australian Council on Healthcare Standards

Author

Segelov, E, Carrington, C, Aranda, S, Currow, D, Zalcberg, JR, Heriot, AG, Mileshkin, L, Coutsouvelis, J, Millar, JL, Collopy, BT, Emery, JD, Zhang, P, Cooper, S, O'Kane, C, Wale, J, Hancock, SJ, Sulkowski, A, Bashford, J, Segelov, E, Carrington, C, Aranda, S, Currow, D, Zalcberg, JR, Heriot, AG, Mileshkin, L, Coutsouvelis, J, Millar, JL, Collopy, BT, Emery, JD, Zhang, P, Cooper, S, O'Kane, C, Wale, J, Hancock, SJ, Sulkowski, A, and Bashford, J

Abstract

INTRODUCTION: The Australian Council on Healthcare Standards (ACHS) sponsored an expert-led, consensus-driven, four-stage process, based on a modified Delphi methodology, to determine a set of clinical indicators as quality measures of cancer service provision in Australia. This was done in response to requests from institutional health care providers seeking accreditation, which were additional and complementary to the existing radiation oncology set. The steering group members comprised multidisciplinary key opinion leaders and a consumer representative. Five additional participants constituted the stakeholder group, who deliberated on the final indicator set. METHODS AND RECOMMENDATIONS: An initial meeting of the steering group scoped the high level nature of the desired set. In stage 2, 65 candidate indicators were identified by a literature review and a search of international metrics. These were ranked by survey, based on ease of data accessibility and collectability and clinical relevance. The top 27 candidates were debated by the stakeholder group and culled to a final set of 16 indicators. A user manual was created with indicators mapped to clinical codes. The indicator set was ratified by the Clinical Oncology Society of Australia and is now available for use by health care organisations participating in the ACHS Clinical Indicator Program. This inaugural cancer clinical indicator set covers high level assessment of various critical processes in cancer service provision in Australia. Regular reviews and updates will ensure usability. CHANGES IN MANAGEMENT AS A RESULT OF THIS STATEMENT: This is the inaugural indicator set for cancer care for use across Australia and internationally under the ACHS Clinical Indicator Program. Multidisciplinary involvement through a modified Delphi process selected indicators representing both generic and specific aspects of care across the cancer journey pathway and will provide a functional tool to compare health care delive

Published
2021

2. Serum L-arginine and endogenous methylarginine concentrations predict irritable bowel syndrome in adults: A nested case-control study.

Author

McEvoy MA, Attia JR, Oldmeadow C, Holliday E, Smith WT, Mangoni AA, Peel R, Hancock SJ, Walker MM, and Talley NJ

Subjects
Aged, Aged, 80 and over, Biomarkers blood, Case-Control Studies, Cohort Studies, Female, Humans, Irritable Bowel Syndrome diagnosis, Irritable Bowel Syndrome psychology, Logistic Models, Male, Middle Aged, Odds Ratio, Psychological Distress, ROC Curve, Arginine analogs & derivatives, Arginine blood, Irritable Bowel Syndrome blood, Nitric Oxide biosynthesis
Abstract

BACKGROUND & AIMS: Nitric oxide, a major inhibitory nonadrenergic, noncholinergic neurotransmitter that relaxes smooth muscle, may be implicated in the pathophysiology of visceral hypersensitivity in irritable bowel syndrome (IBS). Impaired bioavailability of the nitric oxide precursor molecule L-arginine and higher concentrations of methylarginines (endogenous inhibitors of nitric oxide synthesis) are known to impair nitric oxide synthesis in numerous gastrointestinal cell types. We therefore examined serum concentrations of L-arginine and the methylarginines in a nested case-control study, to assess whether these factors are associated with adult IBS., Methods: Data on clinical characteristics, methylarginines, and L-arginine (measured using LC-MS/MS) were collected from a random population-based cohort of Australian adults (median age = 64 years; IQR = 60-70). Cases of IBS, defined according to Rome III criteria (N = 156), and controls (N = 332) were identified from within the cohort at the 5-year follow-up., Results: In adjusted logistic regression analyses, L-arginine, asymmetric dimethylarginine, symmetric dimethylarginine, L-arginine/asymmetric dimethylarginine ratio, and Kessler-10 psychological distress scores were significantly associated with IBS (p < 0.05). [Correction added on 18 September 2021, after first online publication: In the preceding sentence, the value (p > 0.05) has been changed to (p < 0.05)]. Similar results were found for IBS subtypes. Higher serum L-arginine concentration had the strongest association with IBS diagnosis, with an odds ratio of 9.03 for those with serum L-arginine at the 75th (84 μmol/L) versus 25th (46 μmol/L) percentile (95% CI: 5.99-13.62). L-arginine had the best discriminative ability with a bias-adjusted area under the receiver operator characteristic curve of 0.859., Conclusions: Higher serum concentrations of L-arginine and endogenous methylarginines are strongly associated with IBS in adults., (© 2021 The Authors. United European Gastroenterology Journal published by Wiley Periodicals LLC. on behalf of United European Gastroenterology.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results